Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Todd Robert Golub, M.D.

Co-Author

This page shows the publications co-authored by Todd Golub and Rameen Beroukhim.
Connection Strength

1.810
  1. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019 02; 19(2):97-109.
    View in: PubMed
    Score: 0.213
  2. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
    View in: PubMed
    Score: 0.206
  3. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017 Nov; 49(11):1567-1575.
    View in: PubMed
    Score: 0.194
  4. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
    View in: PubMed
    Score: 0.163
  5. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012 Apr 17; 21(4):547-62.
    View in: PubMed
    Score: 0.133
  6. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.114
  7. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009 Jan; 27(1):77-83.
    View in: PubMed
    Score: 0.106
  8. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.098
  9. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021 02; 590(7846):486-491.
    View in: PubMed
    Score: 0.061
  10. Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 Jul; 52(7):748-749.
    View in: PubMed
    Score: 0.059
  11. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 07; 52(7):662-668.
    View in: PubMed
    Score: 0.058
  12. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
    View in: PubMed
    Score: 0.051
  13. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
    View in: PubMed
    Score: 0.051
  14. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
    View in: PubMed
    Score: 0.050
  15. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.050
  16. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013 May; 45(5):478-86.
    View in: PubMed
    Score: 0.035
  17. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
    View in: PubMed
    Score: 0.034
  18. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.034
  19. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8.
    View in: PubMed
    Score: 0.027
  20. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
    View in: PubMed
    Score: 0.026
  21. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.025
  22. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.